Stratagene in Settlement Talks with Applera, Third Wave; Calls Bayer Pact 'Sound' Despite Siemens Buy | GenomeWeb

Stratagene is involved in settlement discussions with Applera and Third Wave Technologies in two separate cases, according to court documents filed over the past month.

Resolving the disputes could decrease Stratagene's legal expenses — around $5.3 million in 2005 — and erase concerns among potential partners that the firm's products may infringe other technologies. It could also provide a boost to Stratagene's sagging stock, which has hovered around its 52-week low for most of the past month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.